Considerable losses and extended timelines for drug approval are keeping ProMetic Life Sciences (Pro... Read More
Echelon Wealth Partners analyst Douglas Loe says ProMetic Life Sciences (ProMetic Life Sciences Stoc... Read More
It looks like fans of Prometic Life Sciences (Prometic Life Sciences Stock Quote, Chart TSX:PLI) are... Read More
Analyst Douglas Loe of Echelon Wealth Partners has lowered his rating from “Speculative Buy” to ... Read More
A new development for ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) has... Read More
Biopharm company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) announce... Read More
Biopharmaceutical company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI)... Read More
Some good news for ProMetic Life Sciences (TSX:PLI) isn’t moving the needle for Echelon Wealth... Read More
Lengthening timelines for the commercialization of its drug Ryplazim are a negative for ProMetic Lif... Read More
Prometic Life Sciences (Prometic Life Sciences Stock Quote, Chart, News: TSX:PLI) may have seen its ... Read More
Delays in launching its first major drug are cause for a target price reduction for Prometic Life Sc... Read More
A “significant unanticipated” delay has Paradigm Capital analyst Rahul Sarugaser aggress... Read More
With the stock down sharply for much of the year, 2017 was a period of time that shareholders of Pro... Read More
Will this be a banner year for Canada’s Life Sciences sector? After a poor showing in 2016, last y... Read More
The company needs to be wary of its burn rate, but Canaccord Genuity analyst Neil Maruoka sees plent... Read More
A dilutive financing has Canaccord Genuity analyst Neil Maruoka lowering his price target on ProMeti... Read More
ProMetic Life Sciences’ (ProMetic Life Sciences Stock Quote, Chart, News: TSX:PLI) IPF treatme... Read More
New data from ProMetic Life Sciences’ (ProMetic Life Sciences Stock Quote, Chart, News: TSX:PL... Read More